VYNE Therapeutics (VYNE) Cash & Current Investments (2016 - 2026)
VYNE Therapeutics (VYNE) posted Cash & Current Investments of $24.9 million for Q1 2026, down 14.07% on a QoQ basis from $29.0 million in Q4 2025, and down 50.41% year-over-year from $50.3 million in Q1 2025.
VYNE Therapeutics (VYNE) Cash & Current Investments (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Cash & Current Investments history runs 11 years deep, the most recent figure standing at $24.9 million for Q1 2026.
- Quarterly Cash & Current Investments fell 50.41% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (down 50.41% YoY) and the FY2025 annual result came in at $29.0 million, down 52.84% from the prior year.
- Cash & Current Investments was $24.9 million for Q1 2026 at VYNE Therapeutics, down from $29.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $86.0 million in Q1 2024 and bottomed at $54000.0 in Q3 2023.
- A 5-year average of $40.7 million and a median of $41.2 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 99.87% — and 2024, when it surged 129872.22%.
- VYNE Therapeutics' Cash & Current Investments stood at $67000.0 in 2022, then jumped by 93462.69% to $62.7 million in 2023, then dropped by 1.87% to $61.5 million in 2024, then tumbled by 52.84% to $29.0 million in 2025, then declined by 14.07% to $24.9 million in 2026.
- Business Quant data shows VYNE's Cash & Current Investments at $24.9 million in Q1 2026, $29.0 million in Q4 2025, and $39.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 24.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.93 Mn |
| Dec 31, 2025 | 29.01 Mn |
| Jun 30, 2025 | 39.65 Mn |
| Mar 31, 2025 | 50.27 Mn |
| Dec 31, 2024 | 61.52 Mn |
| Sep 30, 2024 | 70.19 Mn |
| Jun 30, 2024 | 78.10 Mn |
| Mar 31, 2024 | 85.95 Mn |
| Dec 31, 2023 | 62.69 Mn |
| Sep 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 20.63 Mn |
| Mar 31, 2023 | 67,000.00 |
| Dec 31, 2022 | 67,000.00 |
| Sep 30, 2022 | 35.51 Mn |
| Jun 30, 2022 | 42.81 Mn |
| Mar 31, 2022 | 50.50 Mn |
| Dec 31, 2021 | 605,000.00 |
| Sep 30, 2021 | 52.31 Mn |
| Jun 30, 2021 | 605,000.00 |
| Mar 31, 2021 | 119.54 Mn |